)
)
)
Harness Therapeutics
Our ASO-based MISBA and MISBA Duo platforms block miRNA degradation of targets to enable controlled increases in target protein or simultaneous modulation of two targets, to allow targets involved in complex biology to be addressed. We are building a portfolio of validated and first-in-class targets with disease modification potential in neurodegeneration.
Our lead programme for Huntington’s disease upregulates FAN1 nuclease to slow somatic expansion. Our candidate will enter preclinical studies in 1Q26 with clinical start planned for early 2027.
Our portfolio includes first-in-class, genetically validated targets for ALS, AD and PD
Harness has been funded by Takeda Ventures, Dementia Discovery Fund (SV Health) Epidarex Capital and Ono Ventures.
We are seeking a ~$70m during 2025 which will deliver initial clinical data for HD and a 2nd programme to CTA.
We are also seeking partnerships on both our targets and partner targets which can leverage our platform..
Address
CambridgeCambridgeshire
United Kingdom
)
){kind=logo}
)
){kind=logo}
){kind=logo}
)
)
)
)